This study did not confirm that UHR 12 out of 12 HLA matching increases the probability of overall survival but does demonstrate that aGVHD risk, and in certain settings TRM, is lowest in UHR ...

The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant ...

CareDx CDNA recently announced the launch of AlloSeq Nano, a nanopore-based HLA (human leukocyte antigen) and ABO genotyping ...

OSLO, Norway--(BUSINESS WIRE)--NEC OncoImmunity AS (NOI) today announced a publication that describes a novel approach to type new HLA alleles and characterize the HLA of tumors to guide personalized ...

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of ...

DUBLIN--(BUSINESS WIRE)--The "HLA Typing Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent), Application (Cancer Research, Infectious & Non Infectious Diseases, ...

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=39129877 As of 2024, the key players operating in the global HLA typing market are ...

Increased investments in transplantation are driving growth. The global human leukocyte antigen (HLA) typing market is projected to reach $1.7b by 2030 at a compound annual growth rate of 6.7%, ...

The global HLA typing market is expected to expand at a compound annual growth rate (CAGR) of approximately 6% during the forecast period. Market growth is driven by the rising demand for organ and ...